This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market. The company announced the completion of two ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

Novo Nordisk’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial. Rybelsus is an oral form of ...

Novo Nordisk's GLP-1 medication, Rybelsus, reduced major adverse cardiovascular events by 14% compared to a placebo in a phase 3 trial, the drugmaker said Oct. 21. Rybelsus, a daily pill approved ...

Novo Nordisk plans to seek regulatory approval for Rybelsus label expansion by late 2024 or early 2025. On Monday, Novo Nordisk A/S NVO released the headline results from the SOUL Phase 3 ...

How much will a name-brand 30-day supply of the biggest dose of the "little blue pill" (100 mg ... brand-name drugmakers such ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the ...

Novo Nordisk's once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial. Rybelsus is an oral form of ...

On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial. Last year, Novo Nordisk’s subcutaneous once-weekly (injectable ...